Moderna says FDA needs more time to complete review of its COVID-19 shot for adolescents
The Peninsula
Moderna Inc said on Sunday it has been told that the U.S. Food and Drug Administration will require additional time to complete its assessment of the company's COVID-19 vaccine for use in adolescents aged 12 to 17 years.
The FDA informed Moderna that the review may not be completed before January 2022, the company said in a statement, dealing a potential setback to the timing of an emergency use authorization (EUA) for that age group.
Moderna Chief Executive Stephane Bancel told Reuters last week that based on conversations with the agency, he believed the vaccine would be authorized for those 12 to 17 in the next few weeks.
More Related News